




ELSEVIER

Contents lists available at ScienceDirect

EBioMedicine

journal homepage: [www.elsevier.com/locate/ebiom](http://www.elsevier.com/locate/ebiom)

Research paper

## Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France

Samira Fafi-Kremer<sup>a,b,1,\*</sup>, Timothée Bruel<sup>c,d,e,1,\*\*</sup>, Yoann Madec<sup>f</sup>, Rebecca Grant<sup>f</sup>,  
 Laura Tondeur<sup>f</sup>, Ludivine Grzelak<sup>c,d,e,g</sup>, Isabelle Staropoli<sup>c,d,e</sup>, François Anna<sup>h</sup>, Philippe Souque<sup>i</sup>,  
 Sandrine Fernandes-Pellerin<sup>j,k</sup>, Nathalie Jolly<sup>j</sup>, Charlotte Renaudat<sup>j,k</sup>,  
 Marie-Noëlle Ungeheuer<sup>j,k</sup>, Catherine Schmidt-Mutter<sup>l</sup>, Nicolas Collongues<sup>l,r</sup>, Alexandre Bolle<sup>l</sup>,  
 Aurélie Velay<sup>a,b</sup>, Nicolas Lefebvre<sup>m</sup>, Marie Mielcarek<sup>n</sup>, Nicolas Meyer<sup>n,o</sup>, David Rey<sup>p</sup>,  
 Pierre Charneau<sup>h,i</sup>, Bruno Hoen<sup>q</sup>, Jérôme De Seze<sup>l,r</sup>, Olivier Schwartz<sup>c,d,e,2</sup>, Arnaud Fontanet<sup>f,s,2</sup>

<sup>a</sup> CHU de Strasbourg, Laboratoire de virologie, F-67091 Strasbourg, France<sup>b</sup> Université de Strasbourg, INSERM, IRM UMR\_S 1109, Strasbourg, France<sup>c</sup> Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France<sup>d</sup> CNRS UMR 3569, Paris, France<sup>e</sup> Vaccine Research Institute, Creteil, France<sup>f</sup> Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France<sup>g</sup> Université de Paris, Sorbonne Paris Cité, Paris, France<sup>h</sup> Pasteur-TheraVectys joined unit<sup>i</sup> Molecular Virology & Vaccinology Unit, Department of Virology, Institut Pasteur, Paris, France<sup>j</sup> Center for Translational Science, Institut Pasteur, Paris, France<sup>k</sup> Clinical Investigation & Access to BioResources Platform, Institut Pasteur, Paris, France<sup>l</sup> Centre d'investigation Clinique INSERM 1434, CHU Strasbourg, France<sup>m</sup> CHU de Strasbourg, Service des infectieuses et tropicales, F-67091 Strasbourg, France<sup>n</sup> CHU de Strasbourg, Service de santé Publique, GMRC, F-67091 Strasbourg, France<sup>o</sup> Université de Strasbourg, CNRS, iCUBE UMR 7357, Strasbourg, France<sup>p</sup> CHU de Strasbourg, Pôle SMO, le Trait d'Union, F-67091 Strasbourg, France<sup>q</sup> Direction de la recherche médicale, Institut Pasteur, Paris, France<sup>r</sup> CHU de Strasbourg, Service de Neurologie, F-67091 Strasbourg, France<sup>s</sup> Conservatoire National des Arts et Métiers, PACRI Unit, Paris, France

## ARTICLE INFO

## Article History:

Received 22 May 2020

Revised 10 July 2020

Accepted 10 July 2020

Available online xxx

## Keywords:

sars-cov-2  
 Mild covid-19  
 Antibodies  
 Serology  
 Neutralization

## ABSTRACT

**Background:** The serologic response of individuals with mild forms of SARS-CoV-2 infection is poorly characterized.

**Methods:** Hospital staff who had recovered from mild forms of PCR-confirmed SARS-CoV-2 infection were tested for anti-SARS-CoV-2 antibodies using two assays: a rapid immunodiagnostic test (99.4% specificity) and the S-Flow assay (~99% specificity). The neutralizing activity of the sera was tested with a pseudovirus-based assay.

**Findings:** Of 162 hospital staff who participated in the investigation, 160 reported SARS-CoV-2 infection that had not required hospital admission and were included in these analyses. The median time from symptom onset to blood sample collection was 24 days (IQR: 21–28, range 13–39). The rapid immunodiagnostic test detected antibodies in 153 (95.6%) of the samples and the S-Flow assay in 159 (99.4%), failing to detect antibodies in one sample collected 18 days after symptom onset (the rapid test did not detect antibodies in that patient). Neutralizing antibodies (NAbs) were detected in 79%, 92% and 98% of samples collected 13–20, 21–27 and 28–41 days after symptom onset, respectively ( $P = 0.02$ ).

**Interpretation:** Antibodies against SARS-CoV-2 were detected in virtually all hospital staff sampled from 13 days after the onset of COVID-19 symptoms. This finding supports the use of serologic testing for the diagnosis of individuals who have recovered from SARS-CoV-2 infection. The neutralizing activity of the

\* Corresponding author at: CHU de Strasbourg, Laboratoire de virologie, F-67091 Strasbourg, France.

\*\* Corresponding author at: Virus & Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.

E-mail addresses: [samira.fafi-kremer@chru-strasbourg.fr](mailto:samira.fafi-kremer@chru-strasbourg.fr) (S. Fafi-Kremer), [timothee.brueel@pasteur.fr](mailto:timothee.brueel@pasteur.fr) (T. Bruel).

<sup>1</sup> Co-first authors.

<sup>2</sup> Co-last authors.

<https://doi.org/10.1016/j.ebiom.2020.102915>

2352-3964/© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Please cite this article as: S. Fafi-Kremer et al., Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France, EBioMedicine (2020), <https://doi.org/10.1016/j.ebiom.2020.102915>

antibodies increased overtime. Future studies will help assess the persistence of the humoral response and its associated neutralization capacity in recovered patients.

**Fundings:** The funders had no role in study design, data collection, interpretation, or the decision to submit the work for publication.

© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

## 1. Introduction

A novel human coronavirus that is now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in late 2019. In response, many countries have implemented large scale public health and social measures in an attempt to reduce transmission and minimize the impact of the outbreak. As the benefits of these measures are now becoming apparent in terms of a reduction in the daily incidence of SARS-CoV-2 infections and associated deaths, countries are looking for ways to lift these measures and resume economic and social activities. Ideally, the lifting of measures would occur if the population had built sufficient collective immunity, known as herd immunity, to the point that any reintroduction of the virus would not trigger a new epidemic wave. In this context, it is important to understand the extent to which infection has spread in communities, and to which those who have been infected may be protected from re-infection. This requires further understanding of antibody kinetics following SARS-CoV-2 infection.

Numerous serologic assays are now available [1], which provide information on extent of infection and estimates of protective immunity – that is, protection against re-infection. To date, it is thought that for hospitalised patients with COVID-19, seroconversion occurs within the second week following onset of symptoms, with a median time of 5–12 days for IgM antibodies and 14 days for IgG and IgA [2–7]. However, it remains unclear whether time to seroconversion may differ according to disease severity, and early reports suggest that individuals with mild infection may have delayed or absent seroconversion [3]. Further, the correlation between detection of antibodies generated in response to SARS-CoV-2 infection and protective immunity has not yet been established.

### Research in Context

#### Evidence before this study

Severe and critical forms of Coronavirus disease 2019 (COVID-19) lead to seroconversion and induction of neutralizing antibodies. Less is known about the serological response triggered by mild COVID-19.

#### Added value of this study

Antibodies against SARS-CoV-2 were detected in all but one individual who have recovered from mild COVID-19. Neutralizing activity increases overtime, with 98% of individuals displaying neutralizing antibodies at 28–41 days after symptom onset.

#### Implications of all the available evidence

Our results indicate that virtually all individuals experiencing mild COVID-19 seroconvert 14 days after onset of symptoms. Neutralizing response is delayed from seroconversion, eventually detectable in all seropositive individuals after 4 weeks. Future work is needed to determine the level of protection and how antibodies persist after acute induction.

The first three COVID-19 cases identified in France were reported on 24 January 2020 in travellers returning from Wuhan, China [8]. Between 17 and 24 February, a cluster of SARS-CoV-2 infection was detected in an annual religious gathering attended by 2500 people in Mulhouse, eastern France. Infected individuals went to regional hospitals, and this led to a cluster of infected staff at the Strasbourg University Hospitals from the first week of March. Most of them are young individuals who developed mild forms of disease.

The epidemic in Strasbourg, and specifically, the cluster of infected hospital staff, provides the opportunity to use serologic assays, to assess antibody kinetics in individuals who had recovered from COVID-19 and to understand how this correlates with protective immunity.

## 2. Materials and methods

### 2.1. Participants

Between 6 April and 8 April 2020, all hospital staff from Strasbourg University Hospitals with PCR-confirmed SARS-CoV-2 infection were invited to participate in the investigation. This invitation included doctors, nurses, physiotherapists, dentists, medical students, orderlies, hospital assistants, and hospital administrative staff.

Following informed consent, participants completed a questionnaire which covered sociodemographic information, underlying medical conditions, and details related to SARS-CoV-2 infection, including date of testing, date of symptom onset and a description of symptoms. The symptoms included in the survey were: abdominal pain, ageusia, anosmia, asthenia, dry cough, diarrhea, dyspnea, fever, feeling of fever, headache, chest pain, myalgia, nasal obstruction, nausea, pharyngitis, rhinitis, shivers, sweats, vomiting, other. A 5 mL blood sample was taken from all participants. The ICAREB platform (BRIF code n°BB-0033-00062) of Institut Pasteur collects and manages bioresources following ISO 9001 and NF S 96-900 quality standards [9].

### 2.2. Serologic response measurement

All serum samples were tested for antibody responses to SARS-CoV-2 using two serologic assays: 1) a CE-Marked lateral flow assay for detection of IgM and IgG against the SARS-CoV-2 RBD of the spike protein S developed by Biosynex® (COVID-19 BSS IgG/IgM); 2) the S-Flow assay, a flow-cytometry based assay that measures antibodies binding to the spike protein (S) (*GenBank: QHD43416.1*) expressed at the surface of 293T cells (ATCC® CRL-3216™) [10]. The rapid immunodiagnostic assay COVID-19 BSS IgG/IgM from Biosynex® has been approved by the French National Reference Center with excellent analytical performances (<https://covid-19.sante.gouv.fr/tests>). Combined IgM/IgG result has a specificity of 98% and a sensitivity of 95% for samples >14 after onset of symptoms (data available as a pre-print publication [11]). Two parameters can be calculated with the S-Flow assay: the first is the percentage of cells having captured antibodies, defining the seropositivity. The second is the mean fluorescence intensity (MFI) of this binding, which provides a quantitative measurement of the amount of antibodies and their efficacy [10]. As a control for the S-Flow tests, we included pre-epidemic specimens, providing cut-offs for the S-Flow >99% specificity (data available as a pre-print publication [10] and Fig. 1A). Samples were also tested for


neutralization activity at a single dilution of 1:100 using a viral pseudotype-based assay recently described in a pre-print publication [10]. Briefly, single cycle lentiviral pseudotypes coated with the S protein and encoding for a luciferase reporter gene were preincubated with the serum to be tested at a dilution of 1:100, and added to 293T-ACE2 target cells (*Addgene Plasmid #1786*). The luciferase signal was measured after 48 h. The percentage of neutralization was calculated by comparing the signal obtained with each serum to the signal generated by control negative sera. In some analyses, we categorized the samples according to the extent of neutralization observed at the 1:100 dilution. Neutralizing activities >50% and >80% corresponded to inhibitory dilution 50% (ID50) >100 and ID80 >100, respectively.

### 2.3. Statistical analyses

Seropositivity was defined as the presence of detectable anti-SARS-CoV-2 antibodies. The proportion of seropositive samples was compared by time between onset of symptoms and collection of blood sample using chi-square test.

Antibody neutralizing activity was compared by age, gender, underlying medical conditions, time from symptom onset and type of symptoms using chi-square or Fisher's exact test where appropriate. Logistic regression was used for multivariable analysis.

The S-Flow MFI and neutralization of sera were compared by delay since onset of symptoms using the Kruskal-Wallis non-parametric test. The S-Flow MFI of sera with ID50 and ID80 above or



**Fig. 1.** Analysis of SARS-CoV-2 antibody response. (A) Sera from the 160 HCW were surveyed for anti-SARS-CoV-2 antibodies. S-Flow data are represented by the frequency of S+ cells ( $n = 160$ , left panel) and the median Fluorescence intensity (MFI) in positive samples ( $n = 159$ , middle panel). Historical pre-epidemic samples (pre) were included to determine backgrounds of S Flow ( $n = 140$ ). Each dot represents a sample. Samples were grouped according to the number of days after symptom onset. Statistical analyses were performed using Kruskal-Wallis with Dunn's multiple comparisons test. \*  $p < 0.005$ . n.a.: not applicable (B) Neutralizing activity of the 160 sera. The ability of each serum to neutralize lentiviral S- pseudotypes was assessed at a serum dilution of 1:100. Samples are grouped according to the number of days after symptom onset (left panel); \*  $p < 0.005$  using Kruskal-Wallis with Dunn's multiple comparisons test. For each time group, the frequencies of samples displaying a ID50 > 100 (middle panel) or a ID80 > 100 (right panel) were determined. Each dot represents a sample.; p-values obtained using the Chi-square test. (C) Relationship between serological measurement and neutralizing activity. The S-Flow MFI of samples displaying ID50 and ID80 above or below 100 are depicted. Each dot represents a sample. \*\*\*\*  $p < 0.0001$  Unpaired *t*-test. The statistically significant differences are depicted.

below 100 were compared using Student's *t*-test. The chi-square test was used to evaluate the association between investigated factors and neutralization levels. No sample size calculation was conducted prior to the study, all individuals willing to participate were included. Individuals hospitalized for COVID-19 were excluded from this analysis. Investigators were not blinded with respect to the origin of the samples. Randomisation was not applicable. All analyses were performed using Stata (Stata Corp., College Station, Texas, USA) or GraphPad Prism 8 (GraphPad Software, LLC).

#### 2.4. Ethical considerations

This study was registered with ClinicalTrials.gov (NCT04325646) and received ethical approval by the Comité de Protection des Personnes Ile de France III. Informed consent was obtained from all participants.

### 3. Results

Between 6 April and 8 April 2020, 162 hospital staff from Strasbourg University Hospitals who had recovered from RT-PCR confirmed SARS-CoV-2 infection participated in the investigation. Two individuals who were hospitalized for COVID-19 were excluded from these analyses to determine serologic responses in those with mild forms of COVID-19. Table 1 indicates the characteristics of these 160 hospital staff. The median age was 32 years (inter quartile range (IQR): 26–44) and 50 (31.2%) were males. The majority of participants were medical students (28.1%), doctors (20.0%) or nurses (19.4%).

In terms of possible sources of SARS-CoV-2 infection, 74 (46.2%) reported having had contact with a COVID-19 patient either in the ward or in the emergency room. A further 38 (23.7%) reported having had contact with a COVID-19 case outside the health care setting.

One hundred and fifty five (96.9%) had symptoms consistent with COVID-19 (dry cough, fever, dyspnea, anosmia or ageusia). The median time between onset of symptoms and PCR testing was 2 days (IQR: 1–4), and the median time from onset of symptoms to blood sampling was 24 days (IQR: 21–28, range 13–39).

Fig. 1 and Table 2 indicate the seropositivity rates detected by the three assays and categorized by the delay between onset of symptoms and collection of samples. Across all 160 participants, 159 had detectable anti-SARS-CoV-2 antibodies by S-Flow (99.4% sensitivity). The only participant whose serology was negative with all assays was a 58-year-old male with a body mass index of 32 kg/m<sup>2</sup> and no other risk factors for severe COVID-19 disease. His blood was sampled 18 days after onset of symptoms which persisted at the time of blood collection. As expected, none of the 134 pre-epidemic samples included as controls displayed anti-SARS-CoV-2 antibodies (Fig. 1A). The S-Flow MFI displays a significantly higher signal in individuals sampled at days 28–41 compared to those sampled at days 13–20 (Fig. 1A). These results suggest that the overall amount or the affinity of the antibodies improved with time since onset of symptoms.

The IgM rapid test appeared more sensitive than IgG (overall sensitivity: 88.1% vs 71.2%, respectively), especially at the earlier time-points (Table 2). The combination of IgG and IgM rapid test data increased the sensitivity to 95.6%.

Fig. 1B and Table 3 show the proportion of individuals with a neutralizing activity detectable at a 1:100 dilution of serum, using the pseudovirus neutralization assay. The proportion of samples with neutralizing activity increased over time (Fig. 1B), reflecting the increase of antibody titers observed with the S-Flow. The proportion of individuals with an ID<sub>50</sub> ≥ 100 were 79%, 92% and 98% at 13–20, 21–27 and 28–41 days after symptom onset, respectively (*P* = 0.02) [chi-square test] (Fig. 1B).

The associations between the neutralizing activity and the type of symptoms, age, underlying medical conditions and tobacco use are

**Table 1**  
Characteristics of the 160 hospital staff with PCR-confirmed SARS-CoV-2 infection.

Characteristic	N (%)
Male	50 (31.2)
Age (years), median (IQR)	32 (26–44)
Age group (years)	
≤29	66 (41.3)
30–39	40 (25.0)
40–49	26 (16.2)
≥50	28 (17.5)
Occupation	
Physician	32 (20.0)
Nurse	31 (19.4)
Medical student	45 (28.1)
Orderly	17 (10.6)
Hospital assistant	4 (2.5)
Administrative staff	17 (10.6)
Other	14 (8.8)
Contact with COVID-19 patients	
No	80 (50.0)
Yes	74 (46.3)
Missing	6 (3.7)
Level of potential exposure to COVID-19 patients*	
None	10 (13.5)
Some exposure	27 (36.5)
High exposure	37 (50.0)
Types of care activities**	
Mouth care	15 (40.5)
Intubation	13 (35.1)
Other contact with tracheo-bronchial sputum	16 (43.2)
Nasopharyngeal smear	7 (18.9)
Other	10 (27.0)
Symptoms	
Minor only	5 (3.1)
Major (cough, fever, dyspnea, anosmia and ageusia)	155 (96.9)
Number of major symptoms	
0	5 (3.1)
1	41 (25.6)
2	33 (20.6)
3	35 (21.9)
4	32 (20.0)
5	14 (8.8)
Reported symptoms	
Ageusia	89 (55.6)
Anosmia	76 (47.5)
Asthenia	137 (85.6)
Dry cough	93 (58.1)
Diarrhea	44 (27.5)
Dyspnoea	55 (34.4)
Fever	97 (60.6)
Fever, feeling of	53 (33.1)
Headache	120 (75.0)
Chest pain	46 (28.7)
Abdominal pain	27 (16.9)
Myalgia	112 (70.0)
Nasal obstruction	57 (35.6)
Nausea	21 (13.1)
Pharyngitis	44 (27.5)
Rhinitis	70 (43.7)
Shivers	45 (28.1)
Sweats	55 (34.4)
Vomiting	3 (1.9)
Other	29 (18.1)
Time between onset of symptoms and positive PCR test result (days), median (IQR)	2 (1–4)
Time from onset of symptoms to blood sample collection (days), median (IQR)	24 (21–28)
Time from onset of symptoms to blood sample collection (days)	
7–13	1 (0.6)
14–20	28 (17.5)
21–27	83 (51.9)
≥ 28	48 (30.0)

\* based on 75 participants who reported having contact with COVID-19 patients.

\*\* based on the 37 participants who reported having a care activity with high exposure.

**Table 2**

Seropositivity with the different assays (Rapid test, S-Flow, and pseudoneutralization) according to the time after onset of symptoms.

Time from onset of symptoms (days)	13–20 (n = 29)	21–27 (n = 83)	≥28 (n = 48)	Total	P value (Chi-square test)
Rapid test IgM	26 (89.7)	75 (90.4)	40 (83.3)	141 (88.1)	0.47
Rapid test IgG	14 (48.3)	59 (71.1)	41 (85.4)	114 (71.2)	0.002
Rapid test IgG or IgM	27 (93.1)	80 (96.4)	46 (95.8)	153 (95.6)	0.76
S-Flow	28 (96.5)	83 (100)	48 (100)	159 (99.4)	0.18
Pseudoneutralization ID50 > 100	23 (79.3)	76 (91.6)	47 (97.9)	146 (91.2)	0.020
Pseudoneutralization ID80 > 100	11 (37.9)	44 (53.0)	37 (77.1)	92 (57.5)	0.002

**Table 3**

Proportion of 160 participants with protective immunity according to time since onset of symptoms, type of symptoms, age, underlying medical conditions and tobacco use.

	N	Neutralization ID50 > 100	P value (Chi-square test)	Neutralization ID80 > 100	P value (Chi-square test)
Time between onset of symptoms and collection of blood sample (days)			0.02		0.004
13–20	29	23 (79.3)		11 (37.9)	
21–27	83	76 (91.6)		44 (53.0)	
≥28	48	47 (97.9)		37 (77.0)	
Number of participants with major symptoms			0.87		0.44
0	5	4 (80.0)		3 (60.0)	
1	41	38 (92.7)		29 (70.7)	
2	33	30 (90.9)		16 (48.5)	
3	35	35 (94.3)		20 (57.1)	
4	32	33 (94.3)		16 (50.0)	
5	14	12 (85.7)		8 (57.1)	
Ageusia			0.85		0.39
No	84	77 (91.7)		51 (60.7)	
Yes	76	69 (90.8)		41 (53.9)	
Anosmia			0.21		0.48
No	71	67 (94.4)		43 (60.6)	
Yes	89	79 (88.8)		49 (55.1)	
Dry cough			0.22		0.04
No	67	59 (88.1)		45 (67.2)	
Yes	93	87 (93.5)		47 (50.5)	
Fever			0.15		0.29
No	63	55 (87.3)		33 (52.4)	
Yes	97	91 (93.8)		59 (60.8)	
Gender			0.41		0.07
Male	50	47 (94.0)		34 (68.0)	
Female	110	99 (90.0)		58 (52.7)	
Age group			0.92		0.17
≤29	66	59 (89.4)		33 (50.0)	
30–39	40	37 (92.5)		23 (57.5)	
40–49	26	24 (92.3)		15 (57.7)	
≥50	28	26 (92.9)		21 (75.0)	
BMI			0.22		0.02
<18.5	10	7 (70.0)		3 (30.0)	
18.5–25	105	97 (92.4)		55 (52.4)	
25–30	27	25 (92.6)		19 (70.4)	
≥30	17	16 (94.1)		14 (82.4)	
Missing	1	1 (100)		1 (100)	
Arterial hypertension			0.31		0.03
No	150	136 (90.7)		83 (55.3)	
Yes	10	10 (100)		9 (90.0)	
Asthma			0.02		0.67
No	149	138 (92.6)		85 (57.1)	
Yes	11	8 (72.7)		7 (63.6)	
Flu vaccine			0.02		0.46
No	104	99 (95.2)		62 (59.6)	
Yes	56	47 (83.9)		30 (53.6)	
Blood group			0.26		0.96
A	55	50 (90.9)		31 (56.4)	

(continued)

**Table 3 (Continued)**

	N	Neutralization ID50 > 100	P value (Chi-square test)	Neutralization ID80 > 100	P value (Chi-square test)
B	18	18 (100)		9 (50)	
AB	3	2 (66.7)		2 (66.7)	
O	50	44 (88.0)		30 (60.0)	
Not specified	34	32 (94.1)		20 (58.8)	
Tobacco use			0.57		0.97
No	141	128 (90.8)		81 (57.5)	
Yes	19	18 (94.7)		11 (57.9)	
Exposure to patients			0.32		0.49
None	96	85 (88.5)		52 (54.2)	
Low	27	26 (96.3)		18 (66.7)	
High	37	35 (94.6)		22 (59.5)	

summarized in Table 3. The characteristics associated with neutralizing activity (ID50 > 100) were time since onset of symptoms ( $P = 0.02$ ), absence of asthma ( $P = 0.02$ ), and absence of a flu vaccine ( $P = 0.02$ ) [chi-square test]. In a multivariable model including the three variables, none remained associated with neutralizing activity. We also analysed the association of high neutralizing activity (ID80 ≥ 100) with patients characteristics. High neutralizing activity was associated with time since onset of symptoms ( $P = 0.004$ ), having a dry cough ( $P = 0.04$ ), high BMI ( $P = 0.02$ ), and high blood pressure ( $P = 0.03$ ) [chi-square test]. All these characteristics remained independently associated with high neutralizing activity in multivariable analysis except for high blood pressure ( $P = 0.11$ ) [Logistic regression]. There was no association between neutralizing activity and ageusia, anosmia, or fever.

We next examined the relationship between the extent of antibody response and the neutralizing capacity of the sera. Regardless of the time post-symptom onset, samples with ID50 and ID80 ≥ 100 displayed significantly higher signals in the S-Flow assay (Fig. 1C).

#### 4. Discussion

In this investigation, we described the serologic responses of 160 hospital staff who recovered from PCR-confirmed mild SARS-CoV-2 infection. Most studies published to date have been based on hospitalized patients, and therefore have not been able to evaluate serologic responses in individuals with mild or subclinical infection. Since these individuals are currently understood to represent at least 80% of all SARS-CoV-2 infections [12], it is crucial to assess antibody responses in those with mild disease. In our study, we were able to show that all but one (99.4%) participant had detectable levels of anti-SARS-CoV-2 antibodies from 13 days after onset of symptoms. The differences observed between time to seroconversion across the different assays reflect their sensitivity. The S-Flow assay, which displays a high sensitivity, detected seroconversion in all but one sample. The rapid immunodiagnostic test performed well 21 days after onset of symptoms. The rapid test therefore has utility as a tool for diagnosis in the recovery phase of infection. The neutralization assay

was positive in 91% of the samples, and the extent of neutralization paralleled the levels of signal obtained with the S-Flow.

At the community level, countries that have implemented public health and social measures to limit transmission are now lifting some of these measures. Most of the evidence to date suggests that herd immunity after the first wave of the epidemic will be far from sufficient to provide protection against a second epidemic wave [13]. In our study, neutralizing ID50  $\geq 100$  were found in 91% of the individuals. We further report that the neutralization activity of the serum increases with time, reaching 98% four weeks after the onset of symptoms. Therefore, it is a fair assumption that the majority of individuals with mild COVID-19 generate neutralizing antibodies within a month after onset of symptoms. Although not yet demonstrated, several lines of evidence suggest that the presence of neutralizing antibodies may be associated with protective immunity for SARS-CoV-2 infection. In humans, passive immunotherapy based on transfer of antibodies from recovered COVID-19 patients decreases disease severity [5,6,14,15]. In a monkey model, protection from a second SARS-CoV-2 infection is associated with the presence of neutralizing antibodies in the serum ([16] and pre-print publication [17]). SARS-CoV-2 NABs are known to be present in symptomatic individuals [4,18–20]. In a pre-print study of 175 convalescent patients with mild symptoms, NABs were most often detected 10–15 days after symptom onset [19]. However, about 30% of recovered patients generated low titers of NABs ( $\leq 1:500$ ), even at a later time point [19]. In another pre-print publication, 89% of 624 PCR-confirmed mild COVID-19 patients were positive by ELISA [21]. Individuals with a weakly positive or a negative result were retested after at least 10 days. Only 3 individuals remained negative after this second visit, showing that ELISA titers increase overtime [21]. Our results are in line with these observations and indicate that recovery from mild cases is generally, but not always, associated with high titers of NABs in the serum. Indeed, we report here that one month after the onset of symptoms, 98% and 77% of individuals display Nabs with an ID50 and ID80  $\geq 100$ , respectively. Antibody titers are generally higher in patients with severe or critical diseases [5,19]. Interestingly, in our study, individuals with factors associated with more severe disease (e.g., male sex, high body mass index and high blood pressure), were more likely to have high titers of neutralizing antibodies compared to others. This may be due to a higher antigenic burden in such individuals, which will generate a stronger humoral response, or may, on the contrary, suggest that some antibodies may play a deleterious role during infection [22]. Future studies are warranted to characterize the beneficial or detrimental role of specific antibodies in COVID-19 patients and the minimal titer required for protection.

Our study has some limitations. First, due to the study design, we did not include asymptomatic individuals. PCR tests were only performed on symptomatic individuals, precluding the identification and inclusion of asymptomatic individuals in our cohort. Second, neutralization was performed at a single dilution of 1:100, which does not allow the calculation of an exact titer. Third, we only assessed the response to the S proteins. Of note, recent characterizations of asymptomatic individuals suggest a decreased antibody response in those individuals ([23] and pre-print publication [24]). Future work is needed to comprehensively characterize the antibody response in asymptomatic individuals and minor to mild forms of COVID-19.

For patients with SARS-CoV-1, antibodies persist for at least 2 years after symptomatic infection [25]. In the case of Middle East Respiratory Syndrome (MERS)-CoV, the antibody response is variable, not robust, and often undetectable when disease is mild [26–29]. Future studies will help evaluating the persistence of antibodies upon SARS-CoV-2 infection. The cohort of hospital staff described here provides the opportunity to study the duration of the humoral response and the dynamics of the neutralization capacity of the sera. A clinical and virological assessment of potential

reinfections will also help establishing the links that may exist between the antibody response and immune protection.

## Funding sources

OS lab is funded by Institut Pasteur, ANRS, Sidaction, the Vaccine Research Institute (ANR- 10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), “TIMTAMDEN” ANR-14-CE14-0029, “CHIKV-Viro-Immuno” ANR-14-CE14-0015-01 and the Gilead HIV cure program. LG is supported by the French Ministry of Higher Education, Research and Innovation. SFK lab receives funding from Strasbourg University Hospitals (COVID-HUS ; CE-2020-34). The funders had no role in study design, data collection, interpretation, or the decision to submit the work for publication.

## Authors contribution

Conceptualization and Methodology: SFK, TB, YM, OS, AF.  
Cohort management and sample collection: SFK, YM, RG, LT, SFP, NJ, CR, MNU, CSM, NC, AB, AV, NL, MM, NM, DR., BH, JDS, AF.  
Serological and seroneutralization assays: TB, LG, IS, FA, PS, PC, OS.  
Data assembly and manuscript writing: SFK, TB, YM, RG, LT, OS, AF.  
Funding acquisition: PC, TR, BH, JDS, OS, AF.  
Supervision: OS, AF.

## Data sharing

Data are available upon reasonable request.

## Declaration of Competing Interest

SFK, YM, RG, LT, FA, PS, CSM, NC, AB, AV, NL, MM, NM, DR., BH, JDS and AF have no competing interest to declare. PC is the founder and CSO of TheraVectys. LG, IS, TB, and OS are holder of a provisional patent on the S-Flow assay. Dr. Schwartz has a patent “Methods and products for serological analysis of SARS-COV-2 Infection” pending on the S-Flow assay. Dr. Rey reports grants and personal fees from Mylan, personal fees from ViiV Healthcare, grants from Gilead, grants from Abbvie, outside the submitted work.

## Acknowledgments

We thank the patients and individuals who donated their blood. We thank the ICAREB team for management and distribution of the samples. We thank Cassandre von Platen from the center de recherche translationnel as well as Prof Maria Gonzalez and her team (Service Medecine du Travail) for the preparation and the management of the cohort.

## References

- [1] Krammer F. Serology assays to manage COVID-19. *Science* 2020;368:1060–1. doi: [10.1126/science.abc1227](https://doi.org/10.1126/science.abc1227).
- [2] Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). *Clin Infect Dis Off Publ Infect Dis Soc Am* 2020. doi: [10.1093/cid/ciaa310](https://doi.org/10.1093/cid/ciaa310).
- [3] To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *Lancet Infect Dis* 2020;20:565–74. doi: [10.1016/s1473-3099\(20\)30196-1](https://doi.org/10.1016/s1473-3099(20)30196-1).
- [4] Wölfel R, Corman V.M., Guggemos W., Seilmaier M., Zange S., Müller M.A., et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020;1–5. doi: [10.1038/s41586-020-2196-x](https://doi.org/10.1038/s41586-020-2196-x).
- [5] Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2020. doi: [10.1093/cid/ciaa344](https://doi.org/10.1093/cid/ciaa344).
- [6] Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibody Responses in Coronavirus Disease 2019 Patients. *Emerg Infect Dis* 2020;26. doi: [10.3201/eid2607.200841](https://doi.org/10.3201/eid2607.200841).

- [7] Amanat F., Stadlbauer D., Strohmaier S., Nguyen T.H.O., Chromikova V., McMahon M., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* 2020;1–4. doi: 10.1038/s41591-020-0913-5.
- [8] Stoecklin SB, Rolland P, Silue Y, Mailles A, Campese C, Simonon A, et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. *Eurosurveillanc* 2020;25:2000094. doi: 10.2807/1560-7917.es.2020.25.6.2000094.
- [9] Esterre P, Ait-Saadi A, Arowas L, Chaouche S, Corre-Catelin N, Fanaud C, et al. The ICAREB Platform: a Human Biobank for the Institut Pasteur and Beyond. *Open J Bioresour* 2020;7. doi: 10.5334/ojb.66.
- [10] Grzelak L, Temmam S, Planchais C, Demeret C, Huon C, Guivel F, et al. SARS-CoV-2 serological analysis of COVID-19 hospitalized patients, pauci-symptomatic individuals and blood donors. *Medrxiv* 2020:2020.04.21.20068858. doi: 10.1101/2020.04.21.20068858.
- [11] Velay A, Gallais F, Benotmane I, Wendling M.-J., Danion F, Collange O, et al. Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies. *Biorxiv* 2020:2020.06.16.156166. doi: 10.1101/2020.06.16.156166.
- [12] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis* 2020. doi: 10.1016/s1473-3099(20)30243-7.
- [13] Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. *Science* 2020 eabc3517. doi: 10.1126/science.abc3517.
- [14] Amanat F., Stadlbauer D., Strohmaier S., Nguyen T., Chromikova V., McMahon M., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Medrxiv* 2020:2020.03.17.20037713. doi: 10.1101/2020.03.17.20037713.
- [15] Liu S.T.H., Lin H.-M., Baine I., Wajnberg A., Gumprecht J.P., Rahman F., et al. Convalescent plasma treatment of severe COVID-19: a matched control study. *Medrxiv* 2020:2020.05.20.20102236. doi: 10.1101/2020.05.20.20102236.
- [16] Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science* 2020 eabc4776. doi: 10.1126/science.abc4776.
- [17] Bao L, Deng W., Gao H., Xiao C., Liu J., Xue J., et al. Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2. *Biorxiv* 2020:2020.03.13.990226. doi: 10.1101/2020.03.13.990226.
- [18] Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun* 2020;11:1620. doi: 10.1038/s41467-020-15562-9.
- [19] Wu F., Wang A., Liu M., Wang Q., Chen J., Xia S., et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *Medrxiv* 2020:2020.03.30.20047365. doi: 10.1101/2020.03.30.20047365.
- [20] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;181 271-280.e8. doi: 10.1016/j.cell.2020.02.052.
- [21] Wajnberg A., Mansour M., Leven E., Bouvier N.M., Patel G., Firpo A., et al. Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. *Medrxiv* 2020:2020.04.30.20085613. doi: 10.1101/2020.04.30.20085613.
- [22] Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. *Nat Rev Immunol* 2020;20:339–41. doi: 10.1038/s41577-020-0321-6.
- [23] Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* 2020:1–5. doi: 10.1038/s41591-020-0965-6.
- [24] Brochot E., Demey B., Touze A., Belouzard S., Dubuisson J., Schmit J.-L., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. *Medrxiv* 2020:2020.05.12.20098236. doi: 10.1101/2020.05.12.20098236.
- [25] MO H, ZENG G, REN X, LI H, KE C, TAN Y, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. *Respirology* 2006;11:49–53. doi: 10.1111/j.1440-1843.2006.00783.x.
- [26] Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. *Emerg Infect Dis* 2016;22:1554–61. doi: 10.3201/eid2209.151164.
- [27] Choe PG, Perera RAPM, Park WB, Song K-H, Bang JH, Kim ES, et al. MERS-CoV antibody responses 1 year after symptom onset, South Korea, 2015. *Emerg Infect Dis* 2017;23:1079–84. doi: 10.3201/eid2307.170310.
- [28] Park WB, Perera RAPM, Choe PG, Lau EHY, Choi SJ, Chun JY, et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. *Emerg Infect Dis* 2015;21:2186–9. doi: 10.3201/eid2112.151421.
- [29] Memish ZA, Assiri AM, Al-Tawfiq JA. Middle East respiratory syndrome coronavirus (MERS-CoV) viral shedding in the respiratory tract: an observational analysis with infection control implications. *Int J Infect Dis Ijidd Off Publ Int Soc Infect Dis* 2014;29:307–8. doi: 10.1016/j.ijid.2014.10.002.